SUTRO BIOPHARMA, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.14 USD | +1.47% |
|
+3.24% | -3.50% |
| May. 13 | Sutro Biopharma Q1 Loss Widens, Revenue Rises | MT |
| May. 13 | Earnings Flash (STRO) SUTRO BIOPHARMA Posts Q1 Revenue $13M | MT |
Financials (USD)
| Sales 2024 * | 59.32M | Sales 2025 * | 62.54M | Capitalization | 339M |
|---|---|---|---|---|---|
| Net income 2024 * | -243M | Net income 2025 * | -268M | EV / Sales 2024 * | 1.87 x |
| Net cash position 2024 * | 228M | Net cash position 2025 * | 376M | EV / Sales 2025 * | -0.6 x |
| P/E ratio 2024 * |
-1.17
x | P/E ratio 2025 * |
-1.29
x | Employees | 300 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.99% |
More Fundamentals
* Assessed data
More news
Latest transcript on Sutro Biopharma, Inc.
More recommendations
More press releases
More news
| 1 day | +1.47% | ||
| 1 week | +3.24% | ||
| Current month | +21.94% | ||
| 1 month | +21.05% | ||
| 3 months | -13.84% | ||
| 6 months | +68.29% | ||
| Current year | -3.50% |
1 week
4.01
4.98
1 month
3.355.09
Current year
3.206.13
1 year
2.016.13
3 years
2.0123.70
5 years
2.0128.30
10 years
2.0128.30
| Managers | Title | Age | Since |
|---|---|---|---|
William Newell
CEO | Chief Executive Officer | 66 | 09-01-13 |
Jane Chung
PSD | President | 53 | 21-08-08 |
Edward Albini
DFI | Director of Finance/CFO | 66 | 13-01-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Connie Matsui
CHM | Chairman | 70 | 19-06-23 |
James Panek
BRD | Director/Board Member | 71 | 20-01-06 |
Daniel Petree
BRD | Director/Board Member | 68 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - | |
| 0.01% | 1,487 M€ | +8.80% | - | |
| 0.01% | 9 M€ | +10.11% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 4.14 | +1.47% | 528,017 |
| 24-05-23 | 4.08 | -4.23% | 646,300 |
| 24-05-22 | 4.26 | -6.17% | 1,020,696 |
| 24-05-21 | 4.54 | -2.99% | 2,152,177 |
| 24-05-20 | 4.68 | +16.71% | 4,000,574 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotes
Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Companyâs advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed against folate receptor-alpha (FolRa), for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. It also has two preclinical product candidates, STRO-003 and STRO-004. These product candidates are single homogeneous ADCs directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), and tissue factor (TF), each of which is being developed for the treatment of solid tumors.
Calendar
2024-06-06
- Jefferies Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
4.14
USD
Average target price
12.6
USD
Spread / Average Target
+204.35%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.50% | 339M | |
| +12.30% | 118B | |
| +12.15% | 106B | |
| -8.14% | 23.4B | |
| -1.11% | 21.78B | |
| -9.37% | 18.09B | |
| -41.25% | 16.72B | |
| -15.33% | 15.97B | |
| +5.80% | 14.03B | |
| +28.03% | 11.67B |
- Stock Market
- Equities
- STRO Stock
